RLYB Valuation

Rallybio Corp

Add to Watchlist

Advanced Chart

0.609

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

RLYB Relative Valuation

RLYB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RLYB is overvalued; if below, it's undervalued.

Historical Valuation

Rallybio Corp (RLYB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.44. The fair price of Rallybio Corp (RLYB) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：0.61

Fair

-0.74

Trailing

Forward

0.00

EV/EBITDA

Rallybio Corp. (RLYB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.19. The thresholds are as follows: Strongly Undervalued below -2.03, Undervalued between -2.03 and -1.11, Fairly Valued between 0.73 and -1.11, Overvalued between 0.73 and 1.65, and Strongly Overvalued above 1.65. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.52

EV/EBIT

Rallybio Corp. (RLYB) has a current EV/EBIT of 0.52. The 5-year average EV/EBIT is -1.19. The thresholds are as follows: Strongly Undervalued below -6.92, Undervalued between -6.92 and -4.05, Fairly Valued between 1.67 and -4.05, Overvalued between 1.67 and 4.53, and Strongly Overvalued above 4.53. The current Forward EV/EBIT of 0.52 falls within the Historic Trend Line -Fairly Valued range.

184.51

Rallybio Corp. (RLYB) has a current PS of 184.51. The 5-year average PS is 64.02. The thresholds are as follows: Strongly Undervalued below -244.69, Undervalued between -244.69 and -90.34, Fairly Valued between 218.38 and -90.34, Overvalued between 218.38 and 372.73, and Strongly Overvalued above 372.73. The current Forward PS of 184.51 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Rallybio Corp. (RLYB) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.60. The thresholds are as follows: Strongly Undervalued below -7.46, Undervalued between -7.46 and -5.03, Fairly Valued between -0.16 and -5.03, Overvalued between -0.16 and 2.27, and Strongly Overvalued above 2.27. The current Forward P/OCF of 0.00 falls within the Overvalued range.

0.00

P/FCF

Rallybio Corp. (RLYB) has a current P/FCF of 0.00. The 5-year average P/FCF is -6.13. The thresholds are as follows: Strongly Undervalued below -20.98, Undervalued between -20.98 and -13.55, Fairly Valued between 1.29 and -13.55, Overvalued between 1.29 and 8.72, and Strongly Overvalued above 8.72. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Rallybio Corp (RLYB) has a current Price-to-Book (P/B) ratio of 0.55. Compared to its 3-year average P/B ratio of 0.93 , the current P/B ratio is approximately -40.35% higher. Relative to its 5-year average P/B ratio of 1.13, the current P/B ratio is about -51.16% higher. Rallybio Corp (RLYB) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -100.58%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -75.83% , the current FCF yield is about -100.00% lower.

0.55

P/B

Median3y

0.93

Median5y

1.13

-170.73

FCF Yield

Median3y

-100.58

Median5y

-75.83

Competitors Valuation Multiple

The average P/S ratio for RLYB's competitors is 0.00, providing a benchmark for relative valuation. Rallybio Corp Corp (RLYB) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -29.10%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Lixte Biotechnology Holdings Inc

Enlivex Therapeutics Ltd

Briacell Therapeutics Corp

Loss

19.02M

Performance Decomposition

Market capitalization of RLYB decreased by 47.94% over the past 1 year. The primary factor behind the change was an increase in P/E Change from -0.68 to -0.65.

The secondary factor is the Margin Expansion, contributed -15.71%to the performance.

Overall, the performance of RLYB in the past 1 year is driven by P/E Change. Which is more unsustainable.

-29.10%

299.00K → 212.00K

Revenue Growth

-15.71%

-5.43K → -4.58K

Margin Expansion

-3.13%

-0.68 → -0.65

P/E Change

-47.94%